COST-EFFECTIVENESS ANALYSIS OF SACUBITRIL/VALSARTAN COMPARED WITH STANDARD ACEI THERAPIES FOR HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION IN TAIWAN

被引：1
|
作者：
Fann, C. [1 ]
Chen, S. [2 ]
机构：
[1] Kainan Univ, Taoyuan, Taiwan
[2] Novartis Taiwan, Taipei, Taiwan
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.1239
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV93
引用
收藏
页码：A617 / A617
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF DAPAGLIFLOZIN VERSUS SACUBITRIL/VALSARTAN FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION
    McEwan, P.
    Darlington, O.
    Bergenheim, K.
    Qin, L.
    VALUE IN HEALTH, 2020, 23 : S494 - S494
  • [22] Sacubitril/valsartan or an implantable cardioverter-defibrillator in heart failure with reduced ejection fraction patients: a cost-effectiveness analysis
    Zaca, Valerio
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2018, 19 (10) : 597 - 605
  • [23] Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction
    King, Jordan B.
    Shah, Rashmee U.
    Bress, Adam P.
    Nelson, Richard E.
    Bellows, Brandon K.
    JACC-HEART FAILURE, 2016, 4 (05) : 392 - 402
  • [24] Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction
    Gaziano, Thomas A.
    Fonarow, Gregg C.
    Velazquez, Eric J.
    Morrow, David A.
    Braunwald, Eugene
    Solomon, Scott D.
    JAMA CARDIOLOGY, 2020, 5 (11) : 1236 - 1244
  • [25] Cost-Effectiveness of Sacubitril-Valsartan in Patients Who Have Heart Failure With Reduced Ejection Fraction RESPONSE
    Sandhu, Alexander T.
    Ollendorf, Daniel A.
    Chapman, Richard H.
    Pearson, Steven D.
    Heidenreich, Paul A.
    ANNALS OF INTERNAL MEDICINE, 2017, 166 (08) : 607 - 608
  • [26] Cost-Effectiveness of Sacubitril-Valsartan Compared to Angiotensin-Converting Enzyme Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction
    Febrinasari, Ratih P.
    Putra, Stefanus E.
    Hafizhan, Muhammad
    Probandari, Ari N.
    JOURNAL OF PHARMACY PRACTICE, 2023, 36 (04) : 915 - 924
  • [27] Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina
    Mariano A. Giorgi
    Carlos P. Boissonnet
    Paula Soledad Luque
    Jimena Piastrella
    Carlos Porley
    Fernanda Ditata
    Sergio Volman
    Health Economics Review, 13
  • [28] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN FOR THE TREATMENT OF SYMPTOMATIC CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PORTUGAL
    Alarcao, J.
    Ascencao, R.
    Costa, J.
    Gouveia, M.
    Borges, M.
    VALUE IN HEALTH, 2018, 21 : S104 - S104
  • [29] Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina
    Giorgi, Mariano A.
    Boissonnet, Carlos P.
    Luque, Paula Soledad
    Piastrella, Jimena
    Porley, Carlos
    Ditata, Fernanda
    Volman, Sergio
    HEALTH ECONOMICS REVIEW, 2023, 13 (01)
  • [30] Comparative Cost-Effectiveness of Sacubitril-Valsartan, Dapagliflozin, and Empagliflozin in Heart Failure With Reduced Ejection Fraction
    Parikh, Neil U.
    Dixit, Neal
    Ziaeian, Boback
    Fonarow, Gregg C.
    CIRCULATION, 2022, 146
12345